Akademik Veri Yönetim Sistemi
Mol Biol Rep., cilt.1, sa.2, ss.29-51, 2024 (SCI-Expanded)
Abstract
Background Mesenchymal stem cells (MSCs) have the ability to self-renew and are multi-potent. They are a primary candidate for cell-based therapy due to their potential anti-cancer effects. The aim of this study was to evaluate the in vitro antileukemic effect of Wharton’s Jelly-derived MSC (WJ-MSC) on the leukemic cell lines K562 and HL-60.
Methods In this present study, WJ-MSCs were isolated from human umbilical cord. The cells were incubated according to
the standard culture conditions and characterized by flow cytometry. For experiments, WJ-MSC and leukemic cells were
incubated in the direct co-culture at a ratio of 1:5 (leukemia cells: WJ-MSC). HUVEC cells were used as a non-cancerous
cell line model. The apoptotic effect of WJ-MSCs on the cell lines was analyzed using Annexin V/PI apoptosis assay.
Results After the direct co-culture of WJ-MSCs on leukemic cell lines, we observed anti-leukemic effects by inducing apoptosis. We had two groups of determination apoptosis with and without WJ-MSCs for all cell lines. Increased apoptosis rates
were observed in K562 and HL-60 cell lines, whereas the apoptosis rates in HUVEC cells were low.
Conclusions MSCs are known to inhibit the growth of tumors of both hematopoietic and non-hematopoietic origin in vitro.
In our study, WJ-MSC treatment strongly inhibited the viability of HL-60 and K562 and induced apoptosis. Our results also
provided new insights into the inhibition of tumor growth by WJ-MSCs in vitro. In the future, WJ-MSCs could be used to
inhibit cancer cells in clinical applications.
Keywords WJ-MSC · Leukemia · Co-culture · Anti-leukemic effect · Cell-based therapy